2.1 Malaria Diagnosis & Case Management

Malaria Diagnosis & Case Management

Malaria remains one of the leading causes of morbidity and outpatient clinical consultations in Kenya, contributing substantially to under-five mortality and maternal complications. For candidates preparing for the Clinical Officers Council (COC) licensure examinations, mastery of the four epidemiological strata, rapid diagnostic techniques, exact weight-tiered dosing of artemisinin-based combination therapies (ACTs), life-saving parenteral management of severe malaria, and antenatal chemoprevention protocols is essential.

---

1. Malaria Epidemiology & Stratification in Kenya

Transmission dynamics in Kenya are heterogeneous, governed by altitude, rainfall patterns, ambient temperature, and vector ecology. The predominant malaria parasite in Kenya is Plasmodium falciparum (accounting for >85% to 90% of all infections and virtually all severe disease and deaths). Plasmodium malariae (associated with quartan fever patterns and immune-complex nephrotic syndrome) accounts for roughly 10% of infections, often as co-infections. Plasmodium ovale (tertian fever, dormant liver hypnozoites) accounts for 3% to 5%. Plasmodium vivax has historically been rare in native Kenyan populations due to the high prevalence of the Duffy blood group negative phenotype ($Fy(a-b-)$), which denies merozoites erythrocyte receptor entry; however, transmission is documented in northern nomadic pastoralist communities and among travelers.

The principal vectors are female mosquitoes of the Anopheles gambiae complex (Anopheles gambiae sensu stricto and Anopheles arabiensis) and Anopheles funestus. Peak biting activity occurs indoors between 10:00 PM and 4:00 AM.

Exam Tip: Nairobi City County and central highlands above 1,700m (e.g., Nyandarua, Nyeri) are classified as low-risk or malaria-free zones. Fever in these areas requires a meticulous travel history to endemic regions over the preceding 2 to 4 weeks before presuming indigenous transmission.

---

2. Diagnostic Modalities: mRDT vs. Microscopy

Kenya National Guidelines mandate parasitological confirmation before administering antimalarial therapy ("test before treat"). Presumptive clinical diagnosis is permitted only when diagnostic testing is genuinely inaccessible and referral will cause fatal delay.

Malaria Rapid Diagnostic Tests (mRDTs)

Lateral flow immunochromatographic dipsticks detect specific parasite antigens circulating in peripheral whole blood:

1. Histidine-Rich Protein 2 (HRP-2):
   • Synthesized exclusively by P. falciparum and released from infected red blood cells.
   • Critical Clinical Pitfall: HRP-2 is water-soluble and persists in the bloodstream for 2 to 4 weeks (up to 28 days) after successful parasite clearance by antimalarial drugs. A positive HRP-2 test within 4 weeks of completed treatment cannot differentiate between persistent circulating non-viable antigen and genuine recurrent parasitemia.
   • False negatives can occur due to pfhrp2/pfhrp3 gene deletions or the prozone effect in extreme hyperparasitemia.
2. Parasite Lactate Dehydrogenase (pan-pLDH / Pf-pLDH):
   • Produced only by viable, metabolically active parasites of all human Plasmodium species (pan-pLDH) or P. falciparum (Pf-pLDH).
   • Clears rapidly from the circulation within 24 to 48 hours following effective antimalarial therapy. Useful for assessing early therapeutic response and detecting non-falciparum infections.

Giemsa-Stained Blood Smears (Microscopy Gold Standard)

• Thick Blood Film:
  • Blood is not fixed with methanol; erythrocytes are dehemoglobinized (lysed) during aqueous Giemsa staining.
  • Concentrates parasites 20- to 30-fold compared to thin films, achieving a detection threshold of 10 to 50 parasites/μL.
  • Used for screening, parasite detection, and parasite density quantification.
  • Quantification Formula: Parasites and white blood cells (WBCs) are counted simultaneously under the $100\times$ oil immersion field until 200 WBCs are reached: $\text{Parasite Density (parasites/}\mu\text{L)} = \frac{\text{Parasites Counted}}{\text{WBCs Counted (200)}} \times 8{,}000\text{ WBCs/}\mu\text{L}$
• Thin Blood Film:
  • Fixed with 100% absolute methanol before Giemsa staining, keeping erythrocyte architecture intact.
  • Used for species identification and calculating the percentage parasitemia: $\%\text{ Parasitemia} = \frac{\text{Number of Infected Erythrocytes}}{1{,}000\text{ Total Erythrocytes}} \times 100$
  • Diagnostic Morphological Hallmarks of P. falciparum:
    • Delicate ring-form trophozoites with double chromatin dots ("headphone" appearance).
    • Multiple rings infecting a single erythrocyte.
    • Accolé/applique forms (rings situated on the periphery of the erythrocyte membrane).
    • Crescent- or banana-shaped gametocytes.
    • Absence of intermediate developing trophozoites and schizonts on peripheral smear (due to microvascular cytoadherence and sequestration).

---

3. Case Management: Uncomplicated Malaria

Uncomplicated malaria presents with paroxysms of high-grade fever, chills and rigors, dull generalized headache, arthralgia, myalgia, nausea, and abdominal discomfort without clinical or laboratory evidence of vital organ dysfunction.

First-Line Treatment: Artemether-Lumefantrine (AL)

• Formulation: Fixed-dose combination tablets containing 20 mg Artemether and 120 mg Lumefantrine (Coartem).
• Regimen: A 6-dose regimen administered over 3 days (doses taken at 0, 8, 24, 36, 48, and 60 hours).
• Crucial Pharmacokinetic Administration Rule: Lumefantrine is a highly lipophilic compound. Its systemic bioavailability is enhanced four- to five-fold when co-administered with fatty food, whole milk, or breast milk. Taking AL on an empty stomach leads to subtherapeutic lumefantrine levels, predisposing the patient to recrudescent parasitemia between days 14 and 28.

Second-Line / Alternative Treatment: Dihydroartemisinin-Piperaquine (DHA-PPQ)

• Indications: Treatment failure within 14 to 28 days of completing a full course of AL, severe adverse reactions or contraindications to AL, or clinic stockout.
• Formulation & Dosing: Fixed-dose combination tablets (40 mg DHA / 320 mg Piperaquine phosphate). Administered once daily for 3 consecutive days.
• Administration Rule: Must be swallowed with water on an empty stomach (at least 3 hours after a meal and 3 hours before the next meal). Unlike lumefantrine, co-ingestion of high-fat meals markedly elevates piperaquine peak concentrations, increasing the risk of cardiac QTc interval prolongation and ventricular arrhythmias.

---

4. Severe Malaria: Emergency Resuscitation & Treatment

Severe malaria is a medical emergency caused predominantly by P. falciparum. It results from the sequestration of mature parasitized erythrocytes in the microvasculature of vital organs through binding to endothelial receptors (ICAM-1, CD36, EPCR), causing microvascular obstruction, endothelial inflammation, lactic acidosis, and tissue hypoxia.

WHO & Kenya MOH Diagnostic Criteria for Severe Malaria

The presence of asexual P. falciparum parasitemia combined with at least one of the following clinical or laboratory parameters confirms severe malaria:

1. Impaired Consciousness / Cerebral Malaria: Blantyre Coma Score $\le$2 (in children) or Glasgow Coma Scale (GCS) <11 (in adults), persisting for >30 minutes following the cessation of any convulsion, with non-malaria encephalopathies excluded.
2. Severe Malarial Anemia: Hemoglobin <5.0 g/dL (Hematocrit <15%) in children; Hemoglobin <7.0 g/dL in adults, alongside asexual parasitemia.
3. Acute Kidney Injury (AKI): Oliguria (<0.5 mL/kg/hour in adults; <1.0 mL/kg/hour in children) and serum creatinine >265 μmol/L (3.0 mg/dL) or blood urea >20 mmol/L.
4. Acidosis: Base deficit >8 mEq/L, serum bicarbonate <15 mmol/L, or venous plasma lactate $\ge$5.0 mmol/L. Manifests clinically as respiratory distress (deep, rapid, labored Kussmaul-like acidotic breathing without focal chest signs).
5. Pulmonary Edema / ARDS: Non-cardiogenic pulmonary edema with severe hypoxemia (pulse oximetry $\text{SpO}_2 <90%$ on ambient air).
6. Hypoglycemia: Whole blood glucose <2.2 mmol/L (<40 mg/dL). Common in children and pregnant women treated with quinine.
7. Hyperparasitemia: Parasite density >4% (>200,000 parasites/μL) in low-transmission/non-immune areas, or >10% in high-transmission areas.
8. Prostration / Extreme Weakness: Complete inability to sit, stand, or walk unsupported, or inability to feed/suck in infants.
9. Multiple Convulsions: Two or more generalized epileptic seizures documented within a 24-hour period.
10. Circulatory Collapse / Algid Malaria: Capillary refill time $\ge$3 seconds, cold clammy extremities, weak core pulse, systolic blood pressure <80 mmHg in adults (<70 mmHg in children).
11. Spontaneous Bleeding / Coagulopathy: Disseminated intravascular coagulation (DIC) with bleeding from venipuncture sites, epistaxis, or hematemesis.
12. Jaundice: Serum total bilirubin >50 μmol/L (3.0 mg/dL) with peripheral asexual parasitemia >100,000 parasites/μL.

Parenteral Artesunate: The Drug of Choice

Parenteral Artesunate is superior to IV Quinine, demonstrating a 22.5% reduction in adult mortality (SEAQUAMAT trial) and a 35% reduction in pediatric mortality (AQUAMAT trial), with lower risks of hypoglycemia and arrhythmias.

PARENTERAL ARTESUNATE REGIMEN:

Step 1: Calculate Exact Dose by Body Weight
  • Patients ≥ 20 kg: 2.4 mg/kg IV or IM
  • Children < 20 kg: 3.0 mg/kg IV or IM (higher clearance rate)

Step 2: Dosing Time Points
  • Hour 0 (Admission)
  • Hour 12
  • Hour 24
  • Then Once Daily (every 24 hours) until oral intake tolerated

Step 3: Reconstitution Technique
  • 60 mg vial: Add 1.0 mL of 5% Sodium Bicarbonate ampoule -> Dissolve clear.
  • IV Dilution: Add 5.0 mL of 0.9% Normal Saline or 5% Dextrose (Concentration = 10 mg/mL).
  • IM Dilution: Add 2.0 mL of 0.9% Normal Saline (Concentration = 20 mg/mL).
  • Administer by slow IV push over 1 to 2 minutes.

Step 4: Transition to Oral Medication
  • MUST administer a minimum of 3 parenteral doses (0, 12, 24 hours).
  • Once the patient can swallow, complete a FULL 3-day oral course of Artemether-Lumefantrine (AL).

Alternative: Intravenous Quinine Infusion

• Indication: Used strictly when parenteral artesunate is unavailable.
• Loading Dose: 20 mg quinine dihydrochloride salt/kg body weight diluted in 5% or 10% Dextrose (5–10 mL/kg) infused intravenously over 4 hours.
  • Safety Warning: Omit the loading dose if the patient has received quinine, mefloquine, or quinidine within the preceding 24 hours.
  • NEVER administer IV quinine as a rapid bolus (causes fatal cardiac arrest, profound hypotension, and ventricular fibrillation).
• Maintenance Dose: 10 mg quinine salt/kg infused over 4 hours every 8 hours (starting 8 hours after the start of the loading dose) until the patient can tolerate oral medication (maximum daily dose: 1,800 mg).
• Mandatory Monitoring: Check bedside blood glucose every 4 hours. Quinine potently stimulates pancreatic beta-cell sulfonylurea receptors, inducing hyperinsulinemic hypoglycemia.

Supportive Emergency Care in Severe Malaria

• Fluid Balance: Severe malaria is marked by increased capillary permeability. Avoid aggressive fluid resuscitation. Restrict maintenance IV fluids to 2 to 3 mL/kg/hour to prevent non-cardiogenic pulmonary edema and brain herniation.
• Blood Transfusion: Transfuse with screened packed red blood cells (10 mL/kg) or fresh whole blood (20 mL/kg) only if: (1) Hemoglobin <4.0 g/dL, or (2) Hemoglobin is 4.0 to 5.0 g/dL in the presence of respiratory distress, congestive cardiac failure, or impaired consciousness.
• Hypoglycemia: Correct immediately with 5 mL/kg of 10% Dextrose IV bolus in children (or 50 mL of 50% Dextrose in adults), followed by a 5% or 10% dextrose maintenance infusion.
• Seizure Management: IV Diazepam 0.2 to 0.3 mg/kg slowly over 3 minutes (or rectal diazepam 0.5 mg/kg). If seizures persist beyond 10 minutes, load with IV Phenobarbital (15–20 mg/kg) or IV Phenytoin.

---

5. Malaria in Pregnancy

Pregnancy suppresses cellular immunity and leads to selective parasite sequestration in the placenta, where P. falciparum erythrocyte membrane protein 1 (PfEMP-1) binds to Chondroitin Sulfate A (CSA) on the syncytiotrophoblast. Placental malaria causes maternal severe anemia, spontaneous abortion, stillbirth, preterm delivery, and low birth weight (<2,500g).

Intermittent Preventive Treatment in Pregnancy (IPTp)

• Regimen: Sulfadoxine 500 mg / Pyrimethamine 25 mg (SP) — 3 tablets taken as a single observed dose (total 1,500 mg sulfadoxine / 75 mg pyrimethamine).
• Target Population: All pregnant women attending Antenatal Care (ANC) in malaria-endemic zones (Lake and Coastal regions).
• Timing and Frequency:
  • Start in the second trimester: Exactly from 13 weeks of gestation or upon first quickening.
  • Administer at every scheduled ANC visit, provided there is an interval of at least 4 weeks between doses.
  • The woman should receive a minimum of 3 doses before delivery, but monthly dosing up to delivery is recommended.
• Absolute Contraindications:
  1. First Trimester (<13 weeks): Antifolate mechanism interferes with fetal neural tube closure, carrying high teratogenic risk.
  2. Documented hypersensitivity to sulfonamide antibiotics (risk of Stevens-Johnson Syndrome).
  3. Concurrent administration of Cotrimoxazole preventive therapy (CPT) in HIV-positive pregnant women (SP should not be given; daily CPT provides equivalent antimalarial chemoprophylaxis).
• Interaction with Folic Acid: High-dose folic acid ($\ge$5 mg daily) directly counteracts the antifolate mechanism of pyrimethamine. Pregnant women receiving IPTp-SP should take standard low-dose daily antenatal folic acid (0.4 mg / 400 μg) or have high-dose folic acid withheld for 14 days following each SP dose.

Treatment of Clinical Malaria in Pregnancy

• Uncomplicated Malaria:
  • First Trimester: Oral Quinine plus Clindamycin for 7 days is the historical regimen. However, current WHO and Kenya National Guidelines approve Artemether-Lumefantrine (AL) as first-line across all trimesters when quinine is unavailable, recognizing robust clinical safety data.
  • Second and Third Trimesters: Artemether-Lumefantrine (AL) is the standard first-line treatment.
• Severe Malaria: Intravenous Artesunate (2.4 mg/kg) is the first-line therapy across all trimesters without exception. Saving the mother's life takes absolute precedence, and artesunate significantly reduces maternal mortality compared to quinine.